Politics Rachel Cohrs STAT Plus: Biden administration to fine manufacturers of 27 medicines for price hikes
Politics John Wilkerson STAT Plus: PhRMA chief dings health insurers over drug prices at their own conference
Pharmalot Ed Silverman STAT Plus: Novo Nordisk to lower insulin prices by up to 75% amid growing pressure
Politics Joanne Silberner STAT Plus: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices
Politics John Wilkerson STAT Plus: Biden makes drug pricing a central part of his deficit reduction plans
Pharmalot Ed Silverman STAT Plus: Insulin for $20 a vial? Sanders pushes bill for price caps on the diabetes treatment
Politics Rachel Cohrs STAT Plus: An unlikely new 340B alliance emerges between PhRMA and community health centers
Politics Rachel Cohrs Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government
Pharmalot Ed Silverman STAT Plus: NIH rejects bid to cut a cancer drug’s price by sidestepping patents
Pharmalot Ed Silverman STAT Plus: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%
Pharmalot Ed Silverman STAT Plus: Here’s why there aren’t many cheap, generic versions of pricey inhalers
Politics John Wilkerson STAT Plus: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines
Health Nicholas Florko and Lizzy Lawrence STAT Plus: Science adviser Collins hints at a big White House ask to eliminate hepatitis C
Politics John Wilkerson STAT Plus: By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates
Pharmalot Ed Silverman STAT Plus: U.S. trade rep urged not to sanction countries if they sidestep patents on Vertex cystic fibrosis drugs
Pharmalot Ed Silverman STAT Plus: Canadian drug price board member resigns over government failure ‘to support real change’
Pharmalot Ed Silverman STAT Plus: Lawmakers urge U.S. patent office to scrutinize Merck over ‘abuse’ of the system
Pharmalot Ed Silverman STAT Plus: Dutch group sues AbbVie for human rights violations stemming from Humira pricing
Pharmalot Ed Silverman ‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs
Pharmalot Ed Silverman STAT Plus: French court hands Novartis and Roche another win in battle over antitrust allegations involving eye drug
First Opinion David Mitchell STAT Plus: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs
Politics Rachel Cohrs and John Wilkerson STAT Plus: Biden administration pitches 3 big new drug pricing reform experiments
Politics Rachel Cohrs STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Generic drugmakers may be helped by Inflation Reduction Act; Bayer union warns not to split the company
Politics John Wilkerson STAT Plus: Generics companies fought to stop the new drug pricing law. But they may end up benefiting
First Opinion MacKay Jimeson State of the Union highlights America’s awkward conversation on financing the development of new medicines
Politics Sarah Owermohle and John Wilkerson STAT Plus: In State of the Union, Biden pitches addiction, mental health care policies as opportunities for bipartisanship
Biotech Rachel Cohrs STAT Plus: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices